Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Sponsor: Arena Pharmaceuticals
This PHASE2 trial investigates Ulcerative Colitis and is currently completed. Arena Pharmaceuticals leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Completed PHASE2
-
Feb 2019 — Nov 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Arena Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Barcelona, Spain , Beersheba, Israel , Birmingham, United States , Bridgewater, Canada , Bucharest, Romania , Budapest, Hungary , Bydgoszcz, Poland , Békéscsaba, Hungary , Chernivtsi, Ukraine and 98 more locations